Major Depressive Disorder
Conditions
Brief summary
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684. Information about any side effects that may occur will also be collected.
Interventions
DRUGLY2216684
Administered orally
DRUGPlacebo
Administered orally
DRUGLorazepam
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Are overtly healthy, as determined by medical history and physical examination. * Male participants - Agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug. * Female participants - Are women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or Women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone \[FSH\] \>40 milli-international Units per milliliter \[mIU/mL\]). * Have a body weight \>50 kilogram (kg). * Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator (potassium, magnesium, and calcium values must be within the normal range). * Have venous access sufficient to allow blood sampling as per the protocol. * Have normal blood pressure and pulse rate (sitting position) as determined by the investigator. * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures. * Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site.
Exclusion criteria
* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * Have known allergies to LY2216684, lorazepam, benzodiazepines, or related compounds. * Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to screening. * Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study. * Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data. * Have a history or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation. * Regularly use known drugs of abuse and/or show positive findings on urinary drug screening. * Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies. * Show evidence of hepatitis C and/or positive hepatitis C antibody. * Show evidence of hepatitis B and/or positive hepatitis B surface antigen. * Are women with a positive pregnancy test or women who are lactating. * Intend to use over-the-counter or prescription medication (including hormonal contraceptives) within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor, except for influenza vaccinations. * Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of Uridine 5'-diphospho -glucuronosyltransferase (UGT) within 30 days prior to dosing. * Have donated blood of more than 500 mL within the last month. * Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to each study period and while resident at the clinical research unit (CRU) (1 unit = 12 ounces (oz) or 360 millimeters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits). * Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any participants unwilling to adhere to study caffeine restrictions. * Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment. * Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study. * Have a documented or suspected history of acute narrow angle glaucoma. * Have Gilbert's Syndrome * Participants determined to be unsuitable by the investigator for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax) | Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose | The geometric least squares mean and 90% Confidence Interval are presented. Geometric least squares mean corrected for participant, treatment and random error. |
| Pharmacokinetics of Lorazepam, Time to Maximum Plasma Concentration (Tmax) | Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose | — |
| Pharmacokinetics of Lorazepam, Area Under the Plasma Concentration Curve (AUC) From Time 0 to Infinity (∞) | Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose | The geometric least squares mean and 90% Confidence Interval are presented. Geometric least squares mean corrected for participant, treatment and random error. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Cognitive Function-Digit False Alarms | Baseline, 2, 4, 8 hours on Day 3 | A target digit was pseudo-randomly selected and constantly displayed to the right of the computer screen. A series of digits were then presented in the center of the computer screen at the rate of 150 per minute. The participant was required to press the 'Yes' button as quickly as possible every time a digit in the series matched the target digit. There were 45 targets. The number of false alarms (incorrect 'Yes' responses) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Choice Reaction Time | Baseline, 2, 4, 8 hours on Day 3 | Participants were required to respond to the words 'Yes' and 'No' as they appeared on the computer screen by pressing the corresponding button as quickly as possible. There were 50 trials during which each stimulus word was chosen randomly with equal probability; there was a varying inter-stimulus interval of between 1 and 3.5 seconds. The time required to respond was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Baseline, 2, 4, 8 hours on Day 3 | Participants were required to respond to the words 'Yes' and 'No' as they appeared on the computer screen by pressing the corresponding button as quickly as possible. There were 50 trials during which each stimulus word was chosen randomly with equal probability; there was a varying inter-stimulus interval of between 1 and 3.5 seconds. The percentage of correct responses was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Baseline, 2, 4, 8 hours on Day 3 | Working memory is a sum of accuracy measures from the numeric and spatial working memory tasks (sensitivity index \[SI\]). Working Memory SI is based on how fast the participant responds correctly and how many are correct responses. A high score reflects someone able to hold in memory for a prolonged period. A negative change from baseline reflects impairment compared to baseline. A series of 5 digits were presented on a computer screen, one every 1.15 seconds, for the participant to hold in memory. This was followed by a series of 30 probe digits for each of which the participant had to decide whether it had appeared in the original series of digits and press the corresponding 'Yes' or 'No' response button as quickly as possible. This procedure was repeated 2 times using 2 different series and probes. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Baseline, 2, 4, 8 hours on Day 3 | A series of 5 digits were presented on a computer screen, one every 1.15 seconds, for the participant to hold in memory. This was followed by a series of 30 probe digits for each of which the participant had to decide whether it had appeared in the original series of digits and press the corresponding 'Yes' or 'No' response button as quickly as possible. This procedure was repeated a further 2 times using 2 different series and probes. The time required to press the corresponding 'Yes' or 'No' response button in response to the probe digit is presented. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Baseline, 2, 4, 8 hours on Day 3 | The participant was given a series of words to commit to memory. Immediately after the last word was presented, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The percentage of words correctly recalled (present on the original list of words) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Baseline, 2, 4, 8 hours on Day 3 | The participant was given a series of words to commit to memory. Immediately after the last word was presented, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The number of words incorrectly recalled (not on the original list of words) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Baseline, 2, 4, 8 hours on Day 3 | The participant was given a series of words to commit to memory. After a delay of approximately 15-20 minutes, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The percentage of words correctly recalled (present on the original list of words) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Baseline, 2, 4, 8 hours on Day 3 | The participant was given a series of words to commit to memory. After a delay, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The number of incorrect words was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Simple Reaction Time | Baseline, 2, 4, 8 hours on Day 3 | Participants were instructed to press the 'Yes' response button as quickly as possible every time the word 'Yes' was presented on the computer screen. Fifty stimuli were presented with a varying inter-stimulus interval of between 1 and 3.5 seconds. Participant's reaction time to the stimulus was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Word Recognition Speed | Baseline, 2, 4, 8 hours on Day 3 | The original words from Word Presentation plus 15 distractor words were presented one at a time in a randomized order. For each word, the participant was required to indicate whether they recognized it from the original list of words by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following each response, there was a delay of 1 second before the next word was presented. The time required to press the corresponding 'Yes' or 'No' response button in response to the word was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Baseline, 2, 4, 8 hours on Day 3 | Picture Recognition SI is based on how fast the participant responds correctly and how many are correct responses. SI ranging from zero (chance performance) to one (perfect accuracy). Higher SI indicates better cognitive function. A negative change from baseline reflects impairment compared to baseline. The original pictures from Picture Presentation plus 20 distractor pictures were presented one at a time. For each picture, the participant was required to indicate whether they recognized it from the original series of pictures by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following the response, there was a delay of 1 second before the next pictures was presented. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Picture Recognition Speed | Baseline, 2, 4, 8 hours on Day 3 | The original pictures from Picture Presentation plus 20 distractor pictures were presented one at a time. For each picture, the participant was required to indicate whether they recognized it from the original series of pictures by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following the response, there was a delay of 1 second before the next pictures was presented. The time required to press the corresponding 'Yes' or 'No' response button in response to the picture was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Baseline, 2, 4, 8 hours on Day 3 | The participant used a joystick to track a randomly moving target on the computer screen. The distance from the target was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Postural Stability | Baseline, 2, 4, 8 hours on Day 3 | The ability to stand upright without moving was assessed using equipment modeled on the Wright Ataxia-meter. To measure movements, a cord was attached to the participant who was required to stand for one minute, as still as possible, with feet apart and eyes closed. The amount of sway is expressed as the total angular movement calibrated in units of one-third degree of angle of sway. The amount of sway is expressed as the total angular movement in the antero-posterior plane and calibrated in units of one-third degree of angle of sway. Higher result indicates better postural stability. A negative change from baseline reflects impairment compared to baseline. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Self-rated Alertness | Baseline, 2, 4, 8 hours on Day 3 | The participant was required to rate how they felt at this moment on sixteen 10 centimeter visual analogue scales. The scale endpoints were anchored using polar word pairs such as 'drowsy-alert', 'clumsy-well coordinated', 'mentally slow-quick witted' and 'incompetent-proficient'. Responses from the 16 scales were scored to yield 3 main factors: Self-rated Alertness, Self-rated Contentment, and Self-rated Calmness. The possible range of scores are 0 to 100 for each factor and are represented in millimeters on the 10 centimeter line with higher numbers indicating greater alertness. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Self-rated Contentment | Baseline, 2, 4, 8 hours on Day 3 | The participant was required to rate how they felt at this moment on sixteen 10 centimeter visual analogue scales. The scale endpoints were anchored using polar word pairs such as 'drowsy-alert', 'clumsy-well coordinated', 'mentally slow-quick witted' and 'incompetent-proficient'. Responses from the 16 scales were scored to yield 3 main factors: Self-rated Alertness, Self-rated Contentment, and Self-rated Calmness. The possible range of scores are 0 to 100 for each factor and are represented in millimeters on the 10 centimeter line with higher numbers indicating greater contentment. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Self-rated Calmness | Baseline, 2, 4, 8 hours on Day 3 | The participant was required to rate how they felt at this moment on sixteen 10 centimeter visual analogue scales. The scale endpoints were anchored using polar word pairs such as 'drowsy-alert', 'clumsy-well coordinated', 'mentally slow-quick witted' and 'incompetent-proficient'. Responses from the 16 scales were scored to yield 3 main factors: Self-rated Alertness, Self-rated Contentment, and Self-rated Calmness. The possible range of scores are 0 to 100 for each factor and are represented in millimeters on the 10 centimeter line with higher numbers indicating greater calmness. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Baseline, 2, 4, 8 hours on Day 3 | Word Recognition SI is based on how fast the participant responds correctly and how many are correct responses. SI ranging from zero (chance performance) to one (perfect accuracy). Higher SI indicates better cognitive function. A negative change from baseline reflects impairment compared to baseline. The original words from Word Presentation plus 15 distractor words were presented one at a time in a randomized order. For each word, the participant was required to indicate whether they recognized it from the original list of words by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following each response, there was a delay of 1 second before the next word was presented. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Baseline, 2, 4, 8 hours on Day 3 | A target digit was pseudo-randomly selected and constantly displayed to the right of the computer screen. A series of 450 digits was then presented in the center of the computer screen at the rate of 150 per minute. The participant was required to press the 'Yes' button as quickly as possible every time a digit in the series matched the target digit. There were 45 targets. Percentage of target digits correctly detected was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
| Change From Baseline in Cognitive Function-Digit Vigilance Speed | Baseline, 2, 4, 8 hours on Day 3 | A target digit was pseudo-randomly selected and constantly displayed to the right of the computer screen. A series of 450 digits was then presented in the center of the computer screen at the rate of 150 per minute. The participant was required to press the 'Yes' button as quickly as possible every time a digit in the series matched the target digit. There were 45 targets. Speed at which a participant detected target digits was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Overall All randomized participants | 28 |
| Total | 28 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Second Intervention (6 Days) | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Overall |
|---|---|
| Age, Continuous | 37.9 years STANDARD_DEVIATION 13 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 5 Participants |
| Race/Ethnicity, Customized Multiple | 4 Participants |
| Race/Ethnicity, Customized White | 18 Participants |
| Region of Enrollment United States | 28 Participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 13 / 28 | 3 / 28 | 6 / 28 | 4 / 28 |
| serious Total, serious adverse events | 0 / 28 | 0 / 28 | 0 / 28 | 0 / 28 |
Outcome results
Primary
Pharmacokinetics of Lorazepam, Area Under the Plasma Concentration Curve (AUC) From Time 0 to Infinity (∞)
The geometric least squares mean and 90% Confidence Interval are presented. Geometric least squares mean corrected for participant, treatment and random error.
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose
Population: All enrolled participants
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| LY2216684 + Lorazepam | Pharmacokinetics of Lorazepam, Area Under the Plasma Concentration Curve (AUC) From Time 0 to Infinity (∞) | 207 nanograms*hour per milliliter (ng*h/mL) |
| Placebo + Lorazepam | Pharmacokinetics of Lorazepam, Area Under the Plasma Concentration Curve (AUC) From Time 0 to Infinity (∞) | 199 nanograms*hour per milliliter (ng*h/mL) |
90% CI: [1.01, 1.08]
Primary
Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax)
The geometric least squares mean and 90% Confidence Interval are presented. Geometric least squares mean corrected for participant, treatment and random error.
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose
Population: All enrolled participants.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| LY2216684 + Lorazepam | Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax) | 9.620 nanograms per milliliter (ng/mL) |
| Placebo + Lorazepam | Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax) | 10.720 nanograms per milliliter (ng/mL) |
90% CI: [0.86, 0.94]
Primary
Pharmacokinetics of Lorazepam, Time to Maximum Plasma Concentration (Tmax)
Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post lorazepam dose
Population: All enrolled participants
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| LY2216684 + Lorazepam | Pharmacokinetics of Lorazepam, Time to Maximum Plasma Concentration (Tmax) | 3.00 hours |
| Placebo + Lorazepam | Pharmacokinetics of Lorazepam, Time to Maximum Plasma Concentration (Tmax) | 2.00 hours |
p-value: 0.002190% CI: [0.5, 1]Wilcoxon signed rank test
Secondary
Change From Baseline in Cognitive Function-Choice Reaction Time
Participants were required to respond to the words 'Yes' and 'No' as they appeared on the computer screen by pressing the corresponding button as quickly as possible. There were 50 trials during which each stimulus word was chosen randomly with equal probability; there was a varying inter-stimulus interval of between 1 and 3.5 seconds. The time required to respond was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time | Day 3, 2 hours | 28.2448 millisecond (msec) | Standard Error 12.6614 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time | Day 3, 4 hours | 8.9837 millisecond (msec) | Standard Error 12.6614 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time | Day 3, 8 hours | 9.7930 millisecond (msec) | Standard Error 12.6614 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time | Day 3, 2 hours | 8.4745 millisecond (msec) | Standard Error 12.6614 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time | Day 3, 4 hours | 10.6866 millisecond (msec) | Standard Error 12.6614 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time | Day 3, 8 hours | -13.1780 millisecond (msec) | Standard Error 12.6614 |
Secondary
Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy
Participants were required to respond to the words 'Yes' and 'No' as they appeared on the computer screen by pressing the corresponding button as quickly as possible. There were 50 trials during which each stimulus word was chosen randomly with equal probability; there was a varying inter-stimulus interval of between 1 and 3.5 seconds. The percentage of correct responses was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Day 3, 2 hours | -1.2292 percentage of correct responses | Standard Error 0.7353 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Day 3, 4 hours | -1.3720 percentage of correct responses | Standard Error 0.7353 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Day 3, 8 hours | -0.5863 percentage of correct responses | Standard Error 0.7353 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Day 3, 2 hours | -0.4851 percentage of correct responses | Standard Error 0.7353 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Day 3, 4 hours | -1.2708 percentage of correct responses | Standard Error 0.7353 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Choice Reaction Time Accuracy | Day 3, 8 hours | -1.1994 percentage of correct responses | Standard Error 0.7353 |
Secondary
Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy
The participant was given a series of words to commit to memory. After a delay of approximately 15-20 minutes, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The percentage of words correctly recalled (present on the original list of words) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Day 3, 2 hours | -2.0338 percentage of words correctly recalled | Standard Error 1.8465 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Day 3, 4 hours | -10.8423 percentage of words correctly recalled | Standard Error 1.8465 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Day 3, 8 hours | -11.5566 percentage of words correctly recalled | Standard Error 1.8465 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Day 3, 2 hours | -6.2980 percentage of words correctly recalled | Standard Error 1.8465 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Day 3, 4 hours | -8.2034 percentage of words correctly recalled | Standard Error 1.8465 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Accuracy | Day 3, 8 hours | -6.0595 percentage of words correctly recalled | Standard Error 1.8465 |
Secondary
Change From Baseline in Cognitive Function-Delayed Word Recall Errors
The participant was given a series of words to commit to memory. After a delay, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The number of incorrect words was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Day 3, 4 hours | 0.6535 number of words incorrectly recalled | Standard Error 0.2448 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Day 3, 2 hours | 0.1535 number of words incorrectly recalled | Standard Error 0.2448 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Day 3, 8 hours | 0.6177 number of words incorrectly recalled | Standard Error 0.2448 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Day 3, 2 hours | 0.6323 number of words incorrectly recalled | Standard Error 0.2448 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Day 3, 4 hours | 0.8108 number of words incorrectly recalled | Standard Error 0.2448 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Delayed Word Recall Errors | Day 3, 8 hours | 0.4180 number of words incorrectly recalled | Standard Error 0.2448 |
Secondary
Change From Baseline in Cognitive Function-Digit False Alarms
A target digit was pseudo-randomly selected and constantly displayed to the right of the computer screen. A series of digits were then presented in the center of the computer screen at the rate of 150 per minute. The participant was required to press the 'Yes' button as quickly as possible every time a digit in the series matched the target digit. There were 45 targets. The number of false alarms (incorrect 'Yes' responses) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit False Alarms | Day 3, 2 hours | 1.0204 Number of false alarms | Standard Error 0.3122 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit False Alarms | Day 3, 4 hours | 0.1990 Number of false alarms | Standard Error 0.3122 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit False Alarms | Day 3, 8 hours | 0.4490 Number of false alarms | Standard Error 0.3122 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit False Alarms | Day 3, 2 hours | 0.7296 Number of false alarms | Standard Error 0.3122 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit False Alarms | Day 3, 4 hours | 1.0510 Number of false alarms | Standard Error 0.3122 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit False Alarms | Day 3, 8 hours | 0.7653 Number of false alarms | Standard Error 0.3122 |
Secondary
Change From Baseline in Cognitive Function-Digit Vigilance Speed
A target digit was pseudo-randomly selected and constantly displayed to the right of the computer screen. A series of 450 digits was then presented in the center of the computer screen at the rate of 150 per minute. The participant was required to press the 'Yes' button as quickly as possible every time a digit in the series matched the target digit. There were 45 targets. Speed at which a participant detected target digits was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Speed | Day 3, 2 hours | 20.1712 millisecond (msec) | Standard Error 7.0627 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Speed | Day 3, 4 hours | 14.7702 millisecond (msec) | Standard Error 7.0627 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Speed | Day 3, 8 hours | 9.8277 millisecond (msec) | Standard Error 7.0627 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Speed | Day 3, 2 hours | 12.0238 millisecond (msec) | Standard Error 7.0627 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Speed | Day 3, 4 hours | 12.1391 millisecond (msec) | Standard Error 7.0627 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Speed | Day 3, 8 hours | 2.5073 millisecond (msec) | Standard Error 7.0627 |
Secondary
Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected
A target digit was pseudo-randomly selected and constantly displayed to the right of the computer screen. A series of 450 digits was then presented in the center of the computer screen at the rate of 150 per minute. The participant was required to press the 'Yes' button as quickly as possible every time a digit in the series matched the target digit. There were 45 targets. Percentage of target digits correctly detected was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Day 3, 2 hours | -3.5852 percentage of digits correctly detected | Standard Error 1.3892 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Day 3, 4 hours | -2.4745 percentage of digits correctly detected | Standard Error 1.3892 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Day 3, 8 hours | -2.5534 percentage of digits correctly detected | Standard Error 1.3892 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Day 3, 2 hours | -3.5577 percentage of digits correctly detected | Standard Error 1.3892 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Day 3, 4 hours | -4.1927 percentage of digits correctly detected | Standard Error 1.3892 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Digit Vigilance Targets Detected | Day 3, 8 hours | -1.9702 percentage of digits correctly detected | Standard Error 1.3892 |
Secondary
Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy
The participant was given a series of words to commit to memory. Immediately after the last word was presented, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The percentage of words correctly recalled (present on the original list of words) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Day 3, 2 hours | -2.2751 percentage of words correctly recalled | Standard Error 1.8276 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Day 3, 4 hours | -7.2744 percentage of words correctly recalled | Standard Error 1.8276 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Day 3, 8 hours | -4.4166 percentage of words correctly recalled | Standard Error 1.8276 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Day 3, 2 hours | -3.6767 percentage of words correctly recalled | Standard Error 1.8276 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Day 3, 4 hours | -5.8195 percentage of words correctly recalled | Standard Error 1.8276 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Accuracy | Day 3, 8 hours | -4.1524 percentage of words correctly recalled | Standard Error 1.8276 |
Secondary
Change From Baseline in Cognitive Function-Immediate Word Recall Errors
The participant was given a series of words to commit to memory. Immediately after the last word was presented, the participant was given 1 minute to write as many of the words as possible in any order on a sheet of paper. The number of words incorrectly recalled (not on the original list of words) was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Day 3, 2 hours | -0.1582 number of words incorrectly recalled | Standard Error 0.1494 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Day 3, 4 hours | 0.05605 number of words incorrectly recalled | Standard Error 0.1494 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Day 3, 8 hours | 0.05605 number of words incorrectly recalled | Standard Error 0.1494 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Day 3, 2 hours | 0.1225 number of words incorrectly recalled | Standard Error 0.1494 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Day 3, 4 hours | 0.2297 number of words incorrectly recalled | Standard Error 0.1494 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Immediate Word Recall Errors | Day 3, 8 hours | 0.3011 number of words incorrectly recalled | Standard Error 0.1494 |
Secondary
Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI)
Working memory is a sum of accuracy measures from the numeric and spatial working memory tasks (sensitivity index \[SI\]). Working Memory SI is based on how fast the participant responds correctly and how many are correct responses. A high score reflects someone able to hold in memory for a prolonged period. A negative change from baseline reflects impairment compared to baseline. A series of 5 digits were presented on a computer screen, one every 1.15 seconds, for the participant to hold in memory. This was followed by a series of 30 probe digits for each of which the participant had to decide whether it had appeared in the original series of digits and press the corresponding 'Yes' or 'No' response button as quickly as possible. This procedure was repeated 2 times using 2 different series and probes. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Day 3, 2 hours | -0.00764 Sensitivity Index (SI) | Standard Error 0.02639 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Day 3, 4 hours | -0.02121 Sensitivity Index (SI) | Standard Error 0.02639 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Day 3, 8 hours | 0.007112 Sensitivity Index (SI) | Standard Error 0.02639 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Day 3, 2 hours | 0.003388 Sensitivity Index (SI) | Standard Error 0.02639 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Day 3, 4 hours | -0.00511 Sensitivity Index (SI) | Standard Error 0.02639 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Sensitivity Index (SI) | Day 3, 8 hours | -0.01865 Sensitivity Index (SI) | Standard Error 0.02639 |
Secondary
Change From Baseline in Cognitive Function-Numeric Working Memory Speed
A series of 5 digits were presented on a computer screen, one every 1.15 seconds, for the participant to hold in memory. This was followed by a series of 30 probe digits for each of which the participant had to decide whether it had appeared in the original series of digits and press the corresponding 'Yes' or 'No' response button as quickly as possible. This procedure was repeated a further 2 times using 2 different series and probes. The time required to press the corresponding 'Yes' or 'No' response button in response to the probe digit is presented. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Day 3, 2 hours | 58.2923 milliseconds (msec) | Standard Error 27.7074 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Day 3, 4 hours | 8.1891 milliseconds (msec) | Standard Error 27.7074 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Day 3, 8 hours | -33.6927 milliseconds (msec) | Standard Error 27.7074 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Day 3, 2 hours | 72.0037 milliseconds (msec) | Standard Error 27.7074 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Day 3, 4 hours | 25.5894 milliseconds (msec) | Standard Error 27.7074 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Numeric Working Memory Speed | Day 3, 8 hours | -14.5106 milliseconds (msec) | Standard Error 27.7074 |
Secondary
Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI)
Picture Recognition SI is based on how fast the participant responds correctly and how many are correct responses. SI ranging from zero (chance performance) to one (perfect accuracy). Higher SI indicates better cognitive function. A negative change from baseline reflects impairment compared to baseline. The original pictures from Picture Presentation plus 20 distractor pictures were presented one at a time. For each picture, the participant was required to indicate whether they recognized it from the original series of pictures by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following the response, there was a delay of 1 second before the next pictures was presented. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Day 3, 2 hours | 0.02080 Sensitivity Index | Standard Error 0.04778 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Day 3, 4 hours | -0.04431 Sensitivity Index | Standard Error 0.04778 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Day 3, 8 hours | -0.1054 Sensitivity Index | Standard Error 0.04778 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Day 3, 2 hours | -0.03440 Sensitivity Index | Standard Error 0.04778 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Day 3, 4 hours | -0.06015 Sensitivity Index | Standard Error 0.04778 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Sensitivity Index (SI) | Day 3, 8 hours | -0.09855 Sensitivity Index | Standard Error 0.04778 |
Secondary
Change From Baseline in Cognitive Function-Picture Recognition Speed
The original pictures from Picture Presentation plus 20 distractor pictures were presented one at a time. For each picture, the participant was required to indicate whether they recognized it from the original series of pictures by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following the response, there was a delay of 1 second before the next pictures was presented. The time required to press the corresponding 'Yes' or 'No' response button in response to the picture was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Speed | Day 3, 4 hours | 51.7809 milliseconds (msec) | Standard Error 37.5217 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Speed | Day 3, 2 hours | 57.2341 milliseconds (msec) | Standard Error 37.5217 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Speed | Day 3, 8 hours | -59.9669 milliseconds (msec) | Standard Error 37.5217 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Speed | Day 3, 2 hours | 144.67 milliseconds (msec) | Standard Error 37.5217 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Speed | Day 3, 4 hours | 62.2059 milliseconds (msec) | Standard Error 37.5217 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Picture Recognition Speed | Day 3, 8 hours | -23.2941 milliseconds (msec) | Standard Error 37.5217 |
Secondary
Change From Baseline in Cognitive Function-Postural Stability
The ability to stand upright without moving was assessed using equipment modeled on the Wright Ataxia-meter. To measure movements, a cord was attached to the participant who was required to stand for one minute, as still as possible, with feet apart and eyes closed. The amount of sway is expressed as the total angular movement calibrated in units of one-third degree of angle of sway. The amount of sway is expressed as the total angular movement in the antero-posterior plane and calibrated in units of one-third degree of angle of sway. Higher result indicates better postural stability. A negative change from baseline reflects impairment compared to baseline. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Postural Stability | Day 3, 2 hours | -1.5464 1/3 degree of angle of sway | Standard Error 2.0012 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Postural Stability | Day 3, 4 hours | 0.1965 1/3 degree of angle of sway | Standard Error 2.0012 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Postural Stability | Day 3, 8 hours | -0.9571 1/3 degree of angle of sway | Standard Error 2.0012 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Postural Stability | Day 3, 2 hours | 9.1392 1/3 degree of angle of sway | Standard Error 2.0012 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Postural Stability | Day 3, 4 hours | 2.1857 1/3 degree of angle of sway | Standard Error 2.0012 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Postural Stability | Day 3, 8 hours | -1.6429 1/3 degree of angle of sway | Standard Error 2.0012 |
Secondary
Change From Baseline in Cognitive Function-Self-rated Alertness
The participant was required to rate how they felt at this moment on sixteen 10 centimeter visual analogue scales. The scale endpoints were anchored using polar word pairs such as 'drowsy-alert', 'clumsy-well coordinated', 'mentally slow-quick witted' and 'incompetent-proficient'. Responses from the 16 scales were scored to yield 3 main factors: Self-rated Alertness, Self-rated Contentment, and Self-rated Calmness. The possible range of scores are 0 to 100 for each factor and are represented in millimeters on the 10 centimeter line with higher numbers indicating greater alertness. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Alertness | Day 3, 2 hours | 5.1411 millimeters (mm) | Standard Error 2.4896 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Alertness | Day 3, 4 hours | 3.6887 millimeters (mm) | Standard Error 2.4896 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Alertness | Day 3, 8 hours | 3.7205 millimeters (mm) | Standard Error 2.4896 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Alertness | Day 3, 2 hours | 3.2597 millimeters (mm) | Standard Error 2.4896 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Alertness | Day 3, 4 hours | 4.0018 millimeters (mm) | Standard Error 2.4896 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Alertness | Day 3, 8 hours | 3.1287 millimeters (mm) | Standard Error 2.4896 |
Secondary
Change From Baseline in Cognitive Function-Self-rated Calmness
The participant was required to rate how they felt at this moment on sixteen 10 centimeter visual analogue scales. The scale endpoints were anchored using polar word pairs such as 'drowsy-alert', 'clumsy-well coordinated', 'mentally slow-quick witted' and 'incompetent-proficient'. Responses from the 16 scales were scored to yield 3 main factors: Self-rated Alertness, Self-rated Contentment, and Self-rated Calmness. The possible range of scores are 0 to 100 for each factor and are represented in millimeters on the 10 centimeter line with higher numbers indicating greater calmness. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Calmness | Day 3, 4 hours | 1.4099 millimeters (mm) | Standard Error 1.911 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Calmness | Day 3, 2 hours | -0.9651 millimeters (mm) | Standard Error 1.911 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Calmness | Day 3, 8 hours | 3.4635 millimeters (mm) | Standard Error 1.911 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Calmness | Day 3, 2 hours | 0.3401 millimeters (mm) | Standard Error 1.911 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Calmness | Day 3, 4 hours | -1.3564 millimeters (mm) | Standard Error 1.911 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Calmness | Day 3, 8 hours | 0.3936 millimeters (mm) | Standard Error 1.911 |
Secondary
Change From Baseline in Cognitive Function-Self-rated Contentment
The participant was required to rate how they felt at this moment on sixteen 10 centimeter visual analogue scales. The scale endpoints were anchored using polar word pairs such as 'drowsy-alert', 'clumsy-well coordinated', 'mentally slow-quick witted' and 'incompetent-proficient'. Responses from the 16 scales were scored to yield 3 main factors: Self-rated Alertness, Self-rated Contentment, and Self-rated Calmness. The possible range of scores are 0 to 100 for each factor and are represented in millimeters on the 10 centimeter line with higher numbers indicating greater contentment. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Contentment | Day 3, 2 hours | 3.1100 millimeters (mm) | Standard Error 1.9527 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Contentment | Day 3, 4 hours | 3.0171 millimeters (mm) | Standard Error 1.9527 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Contentment | Day 3, 8 hours | 3.3743 millimeters (mm) | Standard Error 1.9527 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Contentment | Day 3, 2 hours | 1.3686 millimeters (mm) | Standard Error 1.9527 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Contentment | Day 3, 4 hours | 3.3829 millimeters (mm) | Standard Error 1.9527 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Self-rated Contentment | Day 3, 8 hours | 0.01857 millimeters (mm) | Standard Error 1.9527 |
Secondary
Change From Baseline in Cognitive Function-Simple Reaction Time
Participants were instructed to press the 'Yes' response button as quickly as possible every time the word 'Yes' was presented on the computer screen. Fifty stimuli were presented with a varying inter-stimulus interval of between 1 and 3.5 seconds. Participant's reaction time to the stimulus was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Simple Reaction Time | Day 3, 2 hours | 5.0102 millisecond (msec) | Standard Error 8.8823 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Simple Reaction Time | Day 3, 4 hours | 27.9731 millisecond (msec) | Standard Error 8.8823 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Simple Reaction Time | Day 3, 8 hours | 13.1424 millisecond (msec) | Standard Error 8.8823 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Simple Reaction Time | Day 3, 2 hours | 23.9962 millisecond (msec) | Standard Error 8.8823 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Simple Reaction Time | Day 3, 4 hours | 40.0858 millisecond (msec) | Standard Error 8.8823 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Simple Reaction Time | Day 3, 8 hours | 10.0183 millisecond (msec) | Standard Error 8.8823 |
Secondary
Change From Baseline in Cognitive Function-Tracking Average Distance From Target
The participant used a joystick to track a randomly moving target on the computer screen. The distance from the target was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Day 3, 2 hours | 0.3850 millimeters (mm) | Standard Error 2.491 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Day 3, 4 hours | 6.1672 millimeters (mm) | Standard Error 2.491 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Day 3, 8 hours | 0.3743 millimeters (mm) | Standard Error 2.491 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Day 3, 2 hours | -0.3614 millimeters (mm) | Standard Error 2.491 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Day 3, 4 hours | -0.1104 millimeters (mm) | Standard Error 2.491 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Tracking Average Distance From Target | Day 3, 8 hours | -0.6036 millimeters (mm) | Standard Error 2.491 |
Secondary
Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI)
Word Recognition SI is based on how fast the participant responds correctly and how many are correct responses. SI ranging from zero (chance performance) to one (perfect accuracy). Higher SI indicates better cognitive function. A negative change from baseline reflects impairment compared to baseline. The original words from Word Presentation plus 15 distractor words were presented one at a time in a randomized order. For each word, the participant was required to indicate whether they recognized it from the original list of words by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following each response, there was a delay of 1 second before the next word was presented. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Day 3, 2 hours | -0.08834 Sensitivity Index (SI) | Standard Error 0.04199 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Day 3, 8 hours | -0.1523 Sensitivity Index (SI) | Standard Error 0.04199 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Day 3, 4 hours | -0.06242 Sensitivity Index (SI) | Standard Error 0.04199 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Day 3, 4 hours | -0.1983 Sensitivity Index (SI) | Standard Error 0.04199 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Day 3, 8 hours | -0.1524 Sensitivity Index (SI) | Standard Error 0.04199 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Sensitivity Index (SI) | Day 3, 2 hours | -0.07719 Sensitivity Index (SI) | Standard Error 0.04199 |
Secondary
Change From Baseline in Cognitive Function-Word Recognition Speed
The original words from Word Presentation plus 15 distractor words were presented one at a time in a randomized order. For each word, the participant was required to indicate whether they recognized it from the original list of words by pressing the corresponding 'Yes' or 'No' button as quickly as possible. Following each response, there was a delay of 1 second before the next word was presented. The time required to press the corresponding 'Yes' or 'No' response button in response to the word was measured. Participant's response was measured twice. Least squares means were adjusted for baseline, period, sequence, time, treatment and treatment\*time.
Time frame: Baseline, 2, 4, 8 hours on Day 3
Population: All enrolled participants
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Speed | Day 3, 2 hours | -13.7645 milliseconds (msec) | Standard Error 36.5329 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Speed | Day 3, 4 hours | -39.5052 milliseconds (msec) | Standard Error 36.5329 |
| LY2216684 + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Speed | Day 3, 8 hours | -40.9574 milliseconds (msec) | Standard Error 36.5329 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Speed | Day 3, 2 hours | -6.3483 milliseconds (msec) | Standard Error 36.5329 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Speed | Day 3, 4 hours | -25.9919 milliseconds (msec) | Standard Error 36.5329 |
| Placebo + Lorazepam | Change From Baseline in Cognitive Function-Word Recognition Speed | Day 3, 8 hours | -133.24 milliseconds (msec) | Standard Error 36.5329 |